Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.9148 +0.0606 (+7.09%)
Streaming Delayed Price Updated: 11:10 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,424
Open 0.8746
Bid (Size) 0.9104 (3)
Ask (Size) 0.9148 (45)
Prev. Close 0.8542
Today's Range 0.8500 - 0.9299
52wk Range 0.7013 - 11.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third... 
From Fibrobiologics, Inc.
Via GlobeNewswire

Performance

YTD
-53.9%
-53.9%
1 Month
+2.7%
+2.7%
3 Month
-18.3%
-18.3%
6 Month
-61.6%
-61.6%
1 Year
-86.3%
-86.3%

More News

Read More
FibroBiologics Presenting at the ThymUS 2025 Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics Announces 2025 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
From Fibrobiologics, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Thursday's session.
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
From Fibrobiologics, Inc.
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
From D. Boral Capital
Via GlobeNewswire
FibroBiologics Announces $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
From Fibrobiologics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.9148
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 06/06/25 11:10 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS